A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases
Active, not recruitingOBSERVATIONAL
Enrollment
500
Participants
Timeline
Start Date
March 1, 2025
Primary Completion Date
June 30, 2025
Study Completion Date
August 1, 2025
Conditions
Lung Cancer (NSCLC)Leptomeningeal Cancer
Trial Locations (1)
450008
Henan Cancer Hospital, Zhengzhou
All Listed Sponsors
lead
Qiming Wang
OTHER_GOV
NCT06926803 - A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases | Biotech Hunter | Biotech Hunter